RDInvesting Provides Investors with Free In-Depth Equity Reports on EVHC, GHDX, IRWD and ROC

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://www.rdinvesting.com/ and get exclusive access to our numerous stock reports and market updates.

Envision Healthcare Holdings Inc. (NYSE:EVHC - News) shares closed at $26.84 a share Monday. The stock traded between $26.24 and $27.35 on volume of 1.35 million shares traded. Analysts at Credit Suisse have recently initiated coverage on the company with a "neutral" rating and a price target of $29.00. Shares of Envision Healthcare have gained approximately 10.0 percent year-to-date.

Find out more about Envision Healthcare including full access to the free equity report at:
www.RDInvesting.com/EVHC

Genomic Health, Inc. (NASDAQ:GHDX - News) shares declined 4.22 percent to close at $31.09 a share Monday. The stock traded between $30.03 and $31.19 on volume of 210,470 shares traded. Analysts at Raymond James have recently downgraded the company’s rating to "underperform" from "market perform". Shares of Genomic Health have gained approximately 14.0 percent year-to-date.

Find out more about Genomic Health including full access to the free equity report at:
www.RDInvesting.com/GHDX

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - News) shares declined 0.66 percent to close at $12.02 a share Monday. The stock traded between $11.92 and $12.17 on volume of 2.11 million shares traded. Analysts at BMO Capital have recently initiated coverage on the company with a "market perform" rating and a price target of $15.00. Shares of Ironwood Pharmaceuticals have gained approximately 8.0 percent year-to-date.

Find out more about Ironwood Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/IRWD

Rockwood Holdings, Inc. (NYSE:ROC - News) shares declined 2.63 percent to close at $66.16 a share Monday. The stock traded between $65.32 and $67.41 on volume of 1.16 million shares traded. Analysts at Bank of America Merrill Lynch have recently downgraded the company’s rating to "neutral" from "buy". Shares of Rockwood Holdings have gained approximately 33.0 percent year-to-date.

Find out more about Rockwood Holdings including full access to the free equity report at:
www.RDInvesting.com/ROC

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Research Driven Investing
info@rdinvesting.com